Randomisation scheme CRITICS-II trial | Download Scientific Diagram
ASCO-GI 2023: Neo-AEGIS (Neoadjuvant Trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Final primary outcome analysis.
Real-world Scenario: CROSS Regimen as Preoperative Therapy for Oesophageal Squamous Cell Carcinoma | SpringerLink
Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆ - Annals of Oncology
Esophageal Cancer Treatment (PDQ®)–Health Professional Version - NCI
Can the CROSS protocol be safely implemented in real world scenario with broader eligibility criteria? Experience from a tertiary care centre in India - ecancer
Docetaxel regimen extends OS as neoadjuvant therapy for locally advanced esophageal cancer
Cross trial esophagus updated result
Frontiers | Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial
![PDF] Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/630bc6b873bf8304e24a6ac1260e289c3deac5d2/5-Figure1-1.png "PDF] Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol | Semantic Scholar")
PDF] Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol | Semantic Scholar
ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286) – topic of research ...
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial - The Lancet Oncology
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial | Journal of Clinical Oncology
![PDF] Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/630bc6b873bf8304e24a6ac1260e289c3deac5d2/8-Figure2-1.png "PDF] Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol | Semantic Scholar")
PDF] Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol | Semantic Scholar
Definitive concurrent chemoradiotherapy with paclitaxel plus carboplatin is superior to cisplatin plus 5‐fluorouracil in patients with inoperable esophageal squamous cell carcinoma using retrospective, real‐world evidence - Hsieh - 2021 - Cancer Medicine -
Our treatment protocol for a locally advanced (T4) esophageal cancer.... | Download Scientific Diagram
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer | NEJM
Schedule of enrolment, interventions, and assessments | Download Scientific Diagram
Modification of preoperative radiochemotherapy for esophageal cancer (CROSS protocol) is safe and efficient with no impact on surgical morbidity | SpringerLink
Cross trial esophagus updated result
Comparison of outcomes between neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in patients with locally advanced esophageal cancer: A network meta-analysis - eClinicalMedicine
Frontiers | “Targeted” Chemotherapy for Esophageal Cancer
Esophageal Cancer
Cureus | Is a shift in the standard of care chemotherapy for patients with esophageal cancer pre-mature?
Reproducibility of the CROSS Trial Results in the Multimodal Treatment of Esophageal Cancer in Daily Practice: A Single Center Retrospective Observational Study
